Oyster Point

Oyster Point Pharma is a clinical-stage pharmaceutical company focusing on the treatment of ocular surface diseases such as dry eye disease (DED), dedicated to the discovery, development, and commercialization of novel therapies for ocular surface conditions. Oyster Point Pharma's lead product candidate, OC-01 (varenicline), is a highly selective nicotinic acetylcholine receptor (nAChR) agonist currently being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). The novel mechanism of action of OC-01 aims to restore tear film homeostasis by activating the trigeminal parasympathetic pathway and stimulating the glands and cells responsible for natural tear film production.